本期胸小星将为大家带来SBRT与CRT治疗无法手术的Ⅰ期NSCLC:3期随机临床试验;评估ChatGPT作为肺癌手术常见问题的患者资源,一起来看看吧!
2017·EATTS
01
Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial
Anand Swaminath1, Sameer Parpia2, Marcin Wierzbicki3, Vijayananda Kundapur4, Sergio Faria5, Gordon S Okawara1, Theodoros K Tsakiridis1, Naseer Ahmed6, Alexis Bujold7, Khalid Hirmiz8, Timothy Owen9, Nelson Leong10, Kevin Ramchandar11, Edith Filion12, Harold Lau13, Zsolt Gabos14, Robert Thompson15, Brian Yaremko16, Selma Mehiri17, Alexander V Louie18, Kimmen Quan1, Mark N Levine2, James R Wright1, Timothy J Whelan1
1 Department of Oncology, McMaster University, and the Division of Radiation Oncology Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada.
2 Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
3 Juravinski Cancer Centre, Department of Medical Physics, McMaster University, Hamilton, Ontario, Canada.
4 Saskatchewan Cancer Agency, Department of Radiation Oncology, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
5 Department of Radiation Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
6 Section of Radiation Oncology, Department of Radiology, Rady Faculty of Health Sciences, University of Manitoba and CancerCare Manitoba Research Institute, Winnipeg, Manitoba, Canada.
7 Département de Radio-oncologie Clinique-Enseignement-Recherche, Centre intégré universitaire de soins et services sociaux de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont, Montreal, Quebec, Canada.
8 Department of Radiation Oncology, Windsor Regional Cancer Centre, Windsor, Ontario, Canada.
9 Department of Oncology, Queen's University, Cancer Centre of Southeast Ontario at Kingston Health Sciences Centre, Kingston, Ontario, Canada.
10 Allan Blair Cancer Centre, Department of Radiation Oncology, University of Saskatchewan, Regina, Saskatchewan, Canada.
11 Department of Oncology, Northern Ontario School of Medicine, Thunder Bay, Ontario, Canada.
12 Radiation Oncology Department, Centre Hospitalier de l'Université de Montréal, Notre Dame Hospital, Montreal, Quebec, Canada.
13 Department of Oncology, University of Calgary, Calgary, Alberta, Canada.
14 Department of Oncology, University of Alberta, Edmonton, Alberta, Canada.
15 Department of Radiation Oncology, Dalhousie University, Saint John, New Brunswick, Canada.
16 Department of Radiation Oncology, Western University, London, Ontario, Canada.
17 Département de Radio-oncologie, CISSS Montérégie, Hôpital Charles Lemoyne, Montreal, Quebec, Canada.
18 Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Objective:
To examine whether stereotactic body radiotherapy (SBRT) would improve local control (LC) compared with hypofractionated conventional radiotherapy (CRT).
Methods:
This phase 3 randomized clinical trial (RCT) was conducted in 16 Canadian centers. Patients with medically inoperable stage I (≤5 cm) NSCLC were randomized 2:1 to SBRT of 48 Gy in 4 fractions (peripheral NSCLC) or 60 Gy in 8 fractions (central NSCLC) vs CRT of 60 Gy in 15 fractions. Data were collected from May 2014 to January 2020, and data were analyzed from July 2022 to July 2023. The primary objective was to determine the effectiveness of SBRT compared with CRT based on LC at 3 years. Secondary outcomes included event-free survival, overall survival, and toxic effects. All radiation plans were subject to real-time/final review. Local failures were centrally adjudicated. The study was designed to detect a 3-year LC improvement of SBRT from 75% to 87.5%. The target sample size was 324 patients.
Results:
Of 233 included patients, 119 (51.1%) were male, and the mean (SD) age was 75.4 (7.7) years; the median (IQR) follow-up was 36.1 (26.4-52.8) months. A total of 154 patients received SBRT and 79 received CRT. The 3-year LC was 87.6% (95% CI, 81.9%-93.4%) for SBRT and 81.2% (95% CI, 71.9%-90.5%) for CRT (hazard ratio [HR], 0.61; 95% CI, 0.31-1.20; P = 0.15). The HR was 1.02 (95% CI, 0.72-1.45; P = 0.87) for event-free survival and 1.18 (95% CI, 0.80-1.76; P = 0.40) for overall survival. Minimal acute toxic effects were observed. Among those randomized to SBRT, late grade 3 or 4 toxic effects occurred in 5 of 45 (11%) with central NSCLC and 2 of 109 (1.8%) with peripheral NSCLC; among those randomized to CRT, in 1 of 19 (5%) with central NSCLC and 1 of 60 (2%) with peripheral NSCLC. One patient who received SBRT for an ultracentral lesion (target overlapping proximal bronchus) experienced a possible treatment-related grade 5 event (hemoptysis).
Conclusion:
This RCT compared lung SBRT with hypofractionated CRT that included central/ultracentral tumors. No difference was detected in LC between groups. Severe toxic effects were limited, including patients with central tumors. The trial provides important prospective data evaluating SBRT; however, further research is necessary to determine if SBRT is more effective than CRT for peripheral and central NSCLC.
[CITATION]: Swaminath A, Parpia S, Wierzbicki M, et al. Stereotactic vs Hypofractionated Radiotherapy for Inoperable Stage I Non-Small Cell Lung Cancer: The LUSTRE Phase 3 Randomized Clinical Trial. JAMA Oncol. 2024 Sep 19:e243089.
[DOI]: 10.1001/jamaoncol.2024.3089
[IF]: 22.5
向下滑动查看所有内容
胸“星”外科学术团队成员 李佳泽 译
目的
方法
结果
结论
Figure 2. Kaplan-Meier Curves for Outcomes
Table. Worst Toxic Effects By Grade and Tumor Location
2017·EATTS
02
Dana Ferrari-Light1, Robert E Merritt1, Desmond D'Souza1, Mark K Ferguson2, Sebron Harrison3, Maria Lucia Madariaga2, Benjamin E Lee3, Susan D Moffatt-Bruce4, Peter J Kneuertz1
1 Division of Thoracic Surgery, The Ohio State Wexner Medical Center, Columbus OH.
2 Section of Thoracic Surgery, Department of Surgery, The University of Chicago, Chicago IL.
3 Department of Cardiothoracic Surgery, Weill Cornell Medicine/New York Presbyterian Hospital, New York, NY.
4 Beth Israel Lahey Health, Burlington MA.
Objective:
Chat-based artificial intelligence (AI) programs like ChatGPT are re-imagining how patients seek information. This study aims to evaluate the quality and accuracy of ChatGPT-generated answers to common patient questions about lung cancer surgery.
Methods:
A 30-question survey of patient questions about lung cancer surgery was posed to ChatGPT in July 2023. The ChatGPT-generated responses were presented to nine thoracic surgeons at four academic institutions who rated the quality of the answer on a 5-point Likert scale. They also evaluated if the response contained any inaccuracies and were prompted to submit free text comments. Responses were analyzed in aggregate.
Results:
For ChatGPT-generated answers, the average quality ranged from 3.1-4.2 out of 5.0, indicating they were generally "good" or "very good". No answer received a unanimous 1-star (poor quality) or 5-star (excellent quality) score. Minor inaccuracies were found by at least one surgeon in 100% of the answers, and major inaccuracies were found in 36.6%. Regarding ChatGPT, 66.7% of surgeons felt it was an accurate source of information for patients. However, only 55.6% felt they were comparable to answers given by experienced thoracic surgeons, and only 44.4% would recommend it to their patients. Common criticisms of ChatGPT-generated answers included lengthiness, lack of specificity regarding surgical care, and lack of references.
Conclusions:
Chat-based AI programs have potential to become a useful information tool for lung cancer surgery patients. However, the quality and accuracy of ChatGPT-generated answers need improvement before thoracic surgeons could consider this method as a primary education source for patients.
[CITATION]: Ferrari-Light D, Merritt RE, D'Souza D, et al. Evaluating ChatGPT as a Patient Resource for Frequently Asked Questions about Lung Cancer Surgery - A Pilot Study. J Thorac Cardiovasc Surg. 2024 Sep 24:S0022-5223(24)00837-7.
[DOI]: 10.1016/j.jtcvs.2024.09.030.
[IF]: 4.9
向下滑动查看所有内容
胸“星”外科学术团队成员 孙可蒙 译
目的
方法
结果
结论
Table 2. Thoracic surgeon free text comments on additional questions meant to summarize their opinion on ChatGPT-generated answers to common patient questions regarding lung cancer surgery.
Figure 1. Average quality rating for ChatGPT-generated answers to common patient questions regarding lung cancer surgery, grouped by question subject.
2017·EATTS